NCT01307436View on ClinicalTrials.gov

Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines

PHASE3CompletedINTERVENTIONAL

Enrollment

327

Participants

Timeline

Start Date

March 14, 2007

Primary Completion Date

July 8, 2013

Study Completion Date

July 8, 2013

Conditions

Hepatitis A

Interventions

BIOLOGICAL

Epaxal

0.25ml Epaxal: at least 12 IU hepatitis A antigen coupled to immunopotentiating reconstituted influenza virosomes (IRIV)

BIOLOGICAL

Havrix 720

0.5ml Havrix 720: at least 720 EU hepatitis A antigen adsorbed onto aluminium hydroxide

Trial Locations (2)

Unknown

Beersheba

Petah Tikva

All Listed Sponsors

lead

Crucell Holland BV

INDUSTRY

NCT01307436 - Long Term Follow-up of a Study to Assess the Safety and Immunogenicity of a Hepatitis A Vaccine Administered With and in the Absence of DTPaHibIPV, OPV and MMR Vaccines | Biotech Hunter | Biotech Hunter